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Local hematopoietic bone marrow (BM) renin-angiotensin system (RAS) aﬀects the growth, production, proliferation
diﬀerentiation, and function of hematopoietic cells. Angiotensin II (Ang II), the dominant eﬀector peptide of the RAS, regulates
cellular growth in a wide variety of tissues in pathobiological states. RAS, especially Ang II and Ang II type 1 receptor (AT1R),
has considerable proinﬂammatory and proatherogenic eﬀects on the vessel wall, causing progression of atherosclerosis. Recent
investigations, by analyzing several BM chimeric mice whose BM cells were positive or negative for AT1R, disclosed that AT1R in
BM cells participates in the pathogenesis of atherosclerosis.Therefore, AT1R blockingnot only in vascular cells but also in the BM
could be an important therapeutic approach to prevent atherosclerosis.The aim of this paper is to review the function of local BM
RAS in the pathogenesis of atherosclerosis.
1.Introduction
The renin-angiotensin system (RAS) plays a crucial role in
the control of blood pressure, blood ﬂow, ﬂuid volume,
and electrolyte balance, and overactivity of this system
contributes to the pathogenesis of a variety of clinical
conditions, including onset, progression, and outcome of
atherosclerosis [1–3]. Angiotensinogen (AGT) produced in
the liver is the precursor of angiotensin I (Ang I), an inactive
decapeptide that is converted into Ang II, the main eﬀector
of the RAS. Its only role known is as a substrate for renin,
a highly speciﬁc aspartyl protease. Renin that is secreted
from juxtaglomerular apparatus of the kidney cleaves the N-
terminalendofAGTtogenerateAngI.AngIisthenactivated
to the Ang II by angiotensin converting enzyme (ACE),
which is predominantly expressed in high concentrations on
the surface of endothelial cells in the pulmonary circulation
[4].
Ang II plays a main role in the RAS mediated mainly by
two seven transmembrane domain receptors termed Ang II
type 1 receptor (AT1R) and Ang II type 2 receptor (AT2R)
showing a complex pattern of regulation and function [5].
Most of the well-known actions of Ang II-AT1R interaction
causes vasoconstriction and aldosterone release from the
adrenal gland. This classical description of the RAS has been
expanded by recent ﬁndings that RAS is activated locally,
particularly in the vessel wall, heart, the kidney, and the
brain [6–14]. Ang II was also described to be produced by
other enzymes such as chymase, an eﬃcient Ang II-forming
serine protease [15]. It is not aﬀected by ACE inhibition and
has been suggested as relevant for alternative pathways of
AngIIgeneration[16–18].Althoughseveralotheralternative
e n z y m e si n v o l v e di nA n gI If o r m a t i o ns u c ha st o n i na n d
cathepsins, chymase deservesspecial attentionduetoits high
substrate speciﬁcity. The enzyme is also expressed in the
vascular wall, where it has been suggested as a possible player
in Ang II-mediated arteriosclerosis [15].
Inﬂammatory cells detected in atherosclerotic lesions are
mainly originated from bone marrow (BM). The presence
of a locally activated bone marrow (BM) RAS aﬀecting
the growth, production, proliferation, and diﬀerentiation
of hematopoietic cells was suggested in 1996 [19]. Other
than a wide variety of evidences disclosed the existence of a
functionallocalBMRAS.AngiotensinII,throughinteracting2 Cardiology Research and Practice
with AT1 receptor enhances erythroid diﬀerentiation in the
BM [20]. Ang II-stimulated erythroid progenitors formed
signiﬁcantlyhighernumbersofburstformingunit-erythroid
(BFU-E)coloniesin normal human erythropoiesis. Recently,
Fukuda and Sata [21] proposed a hypothesis that the local
RAS in BM plays crucial roles in atherosclerosis. They have
demonstrated that Ang II-AT1R pathway in BM contributes
to atherosclerotic development in the hypercholesterolemic
mice. The aim of this paper is to outline the function of local
BMRASduringthecourseofprogression anddestabilization
of atherosclerosis.
2.RASActivationinAtheroscleroticLesions
2.1. Potential Eﬀects of Activated RAS on Vascular Structure.
Atherosclerosis is a chronic inﬂammatory disease involving
accumulation of lipoproteins and mononuclear cells in the
subendothelial space with a result of a cascade of events in
blood vessels leading to a remodeling of the arterial wall
and a consecutive reduction in lumen size. Novel advances
in biotechnology and molecular methods have enabled us to
understandthemolecularpathwaysthatinduceandpromote
inﬂammatory responses in the formation of atherosclerotic
lesions. Although RAS plays a central role in the control
of blood pressure, ﬂuid volume, and sodium balance,
overactivity of this system contributes to the pathogenesis of
atherosclerosis by simulating a series of coordinated cellular
and molecular events observed in the lesions [22–25].
In the past Ang II was believed to aﬀect atherosclerosis
throughitshemodynamiceﬀects,butinthelasttwodecadeit
hasbeenshown that,directcellulareﬀectsofAng IIaﬀectthe
structural changes in the vessel wall seen in atherosclerosis
[26]. All components of the RAS are expressed in the vessel
wall and mostly the eﬀects of Ang II are mediated by the
G-protein-coupled receptors AT1 and AT2 [27]. Both AT1R
and AT2R have been well identiﬁed in the vessel wall; AT1R
is believed to mediate most of the atherogenic actions of
Ang II [28, 29]. Yang et al. [30]d e m o n s t r a t e dt h a ti n
hypercholesterolemic atherosclerosis in rabbits, the density
of AT1 receptors in the media of diseased blood vessels is
increased ﬁvefold compared to healthy animals. They also
found a signiﬁcant AT1R binding in the neointima of the
diseased arteries. The highest receptor density in the vessel
wall is on vascular smooth muscle cells (VSMCs), but cell
culture studies also established a signiﬁcant AT1R-mediated
responses in endothelial cells and macrophages and AT2Rs
comprise only about 10% of total angiotensin receptors in
healthy blood vessels [30, 31]. Those results suggested that
not only systemic but also local Ang II-AT1R pathway could
contribute to initiation and progression of atherosclerosis in
blood vessels.
2.2. Eﬀects of Activated RAS on Vascular Endothelial Cells.
Ang II, produced locally by endothelial ACE, is one of
the key substances that aﬀects endothelial function (or
dysfunction). To better understand the eﬀect of Ang II on
vascular pathobiology,one must need to examine the pivotal
role of the endothelium in maintaining normal vascular
function and structure. Ang II is synthesized by and has
a key action on the endothelium: it exerts direct inﬂuence
on endothelial function [7, 32]. Vascular endothelium is
known as a metabolically active secretory tissue, presents a
thromboresistant surface to blood, and acts as a selective
macromolecular barrier. It is now believed that structural
abnormalities and function of endothelial cells is the cause
of not only vascular diseases including atherosclerosis but
also certain visceral disorders [33]. Endothelial cells produce
factors that regulate vessel tone, coagulation, cell growth
and death, and leukocyte migration. Under the control of
the endothelium and other factors, VSMCs are also able
to release cytokines and growth-regulatory factors that can
inﬂuence vascular cellular phenotype and growth [7, 34].
Cytokines can exert both pro- and antiatherogenic actions
because theyare multipotentmediators ofinﬂammation and
immunity that can aﬀect key functions of vascular wall cells.
The functions of vascular wall cells regulated by cytokines
mayinﬂuencelesioninitiation,progression,orcomplication.
The cytokines also adjust endothelial functions that control
the development and stability of blood thrombi. Thus,
cytokines can inﬂuence multiple aspects of atherogenesis
and provide new and interesting targets for therapeutic
management [35]. Endothelial cells also regulate vascular
tone in a strict balance between vasodilators-like nitric oxide
(NO), and vasoconstrictors-like Ang II. This balance is
crucial to a healthy endothelium. When Ang II is elevated,
endothelial dysfunction begins. The imbalance toward Ang
II by itself can cause many of the changes in the endothelium
that set the atherosclerotic process in motion [36].
Ang-II upregulates expression of adhesion molecules,
cytokines, and chemokines and exerts a proinﬂammatory
eﬀect on leucocytes, endothelial cells, and VSMCs [22,
24, 26, 37–39]. And also Ang II upregulates expression
of vascular endothelial growth factor (VEGF) which con-
tributes to adventitial angiogenesis [40–42]. Acting via the
type 1 receptor, Ang II initiates an inﬂammatory cascade
of reduced nicotinamide-adenine dinucleotide phosphate
oxidase, reactive oxygen species (ROS), and nuclear factor-
kappa B, which mediates transcription and gene expression
and increases chemokines and adhesion molecules [43].
The Ang II type 1a (AT1a) receptor is expressed on
multiple cell types in atheroscleroticlesions, including bone-
marrow-derived cells and vascular wall cells, and mediates
inﬂammatory and proliferative responses. Indeed, Ang II
infusion accelerates atherogenesis in hyperlipidemic mice
by recruiting monocytes and by activating vascular wall
cells [44]. In advanced atherosclerotic lesions, Ang II stim-
ulates matrix metalloproteinases (MMPs) and plasminogen
activator inhibitor-1 expression, causing destabilization of
atherosclerotic plaque and alteration of ﬁbrinolytic balance
[45–47].
Besides inducing oxidative stress, endothelial damage,
and disease pathology including vasoconstriction, thrombo-
sis, and inﬂammation, Ang II is also involved in vascular
remodeling, acting as a bifunctional growth factor that stim-
ulates production of growth factors and vasoactive agents
(e.g., platelet-derived growth factor, insulin-like growth
factor, and basicﬁbroblastgrowthfactor)inVSMCs[48,49].Cardiology Research and Practice 3
Other mechanisms whereby Ang II may promote vascular
remodeling and formation of vascular lesions are the modu-
lation of vascular cell migration, decreased vascular smooth
muscle apoptosis, and extracellular matrix deposition [50–
52]. These multiple actions of Ang II are mediated via
complex intracellular signaling pathways including stimula-
tion of the PLC-IP3-DAG cascade, tyrosine kinases, MAP
kinases, and RhoA/Rho kinase [53]. Intracellular signaling
pathways that are stimulated after binding of the peptide
to its cell-surface receptors, of which two major subtypes
have been characterized, AT1R and AT2R [54, 55]. Although
Ang IV receptor was identiﬁed recently, as insulin-regulated
aminopeptidase, however, its roles in angiogenesis still
remain unknown. In humans, AT1R is widely expressed
in blood vessels, kidney, heart, liver, and adrenal glands,
whereas AT2R is present largely in foetal tissue, decreasing
quickly after birth, with relatively low amounts normally
expressed in adult tissue [53]. AT1R mediates proangio-
genic eﬀect through enhancement of inﬂammation and
leukocytes inﬁltration, while AT2R mediates antiangiogenic
eﬀect through regulation of apoptosis. AT2R expression
is increased in pathological circumstances associated with
cardiac and vascular remodeling or inﬂammation. Although
they diﬀer in their unique actions, both of the receptors play
a crucial role in regulating VSMC function.
2.3. Reactive Oxygen Species and Inﬂammatory Cells in
the Formation of Atherosclerosis. Experimental and clinical
studies using Ang II, ACE inhibitors, and AT1 receptor
blockershave provided indirect evidence supporting the role
ofoxidativestress in thepathogenesisofendothelialdysfunc-
tion and atherogenesis, independent of the hemodynamic
stress of blood pressure [56, 57]. Growing evidence suggests
that vascular reactive oxygen species (ROS) play a key role in
atherogenesis. Besides its vasoconstrictive properties, Ang II,
via the AT1 receptor, generates O2-production in endothelial
cells, adventitial ﬁbroblasts, vascular smooth muscle cells
(VSMCs), and mesangial cells through activation of nicoti-
namide adenine dinucleotide (reduced form)/NADH phos-
phate (reduced form) (NADH/NAD(P)H) oxidase leading
to endothelial dysfunction, growth, and inﬂammation [58,
59].Among many ROS generator,nicotinamidedinucleotide
phosphate (NAD(P)H) oxidase dependent pathway is an
important one in vascular system [60]. Recent researches
demonstrated that in endothelial cells as well as in VSMCs,
NAD(P)H-dependentoxidaserepresentsthemostsigniﬁcant
O2-source. Interestingly, this oxidase is activated upon
stimulation with Ang II, suggesting that under all conditions
of an activated circulating and/or local RAS endothelial
dysfunction secondary to increased vascular O2-production
is expected. In a previous study by Barry-Lane et al.
[61], it has been demonstrated that NAD(P)H oxidase is
a crucial enzyme in the pathogenesis of atherosclerosis by
analyzing the genetically altered mice that are lacking for
both apolipoprotein E (ApoE) and p47phox, one subunit
of NAD(P)H oxidase. In this interesting study, signiﬁcant
reduction in atherosclerotic lesion was shown in the double
knockout mice, compared with that of ApoE-deﬁcient mice.
ROS takes actions not only as a regulator of vascular tonus
but also as a second messenger to modify the vascular
cell phenotypes. ROS stimulates janus kinase (JAK)/STAT
(signal transducers and activators of transcription), Akt,
and mitogen-activated protein kinase pathways [62–65].
Increased oxidativestress contributesto endothelialdysfunc-
tion and to vascular inﬂammation by stimulating the redox-
sensitive transcription factors (NF-kappa B) and by upregu-
lating adhesion molecules, cytokines, and chemokines.
Inthecardiovascularsystem, themajor catalyticsubunits
of NAD(P)H oxidase are, nox 1, gp91phox (nox 2), and
nox 4, and the regulatory subunits are p22phox, p47phox,
p67phox,andrac[59].Thefourphoxsubunitsareknowntto
be upregulated in endothelial cells and VSMCs from vessels
exposed to Ang II [59]. Ang II induces ROS production,
one of the most signiﬁcant mediators of the atherogenic
actions of RAS. The ROS produced by Ang II contributes to
the pathogenesis of vascular diseases by inactivating nitric
oxide, impairing endothelial function, enhancing VSMC
growth and proliferation, and stimulating proatherogenic,
inﬂammatory, and adhesion molecule expression [66–68].
Importantly, the Ang II-induced elevation in O2-generation
in the vessel wall does not seem to be related to the
hemodynamic eﬀects of Ang II, because norepinephrine-
induced hypertension did not have a similar eﬀect [57].
A n gI Ii sak e ym e d i a t o ro fo x i d a t i v es t r e s sa n d
decreased activity of NO. Ang II causes the activation
of NADH/NADPH oxidase that results in the production
of superoxide anion and, subsequently, hydrogen peroxide
[69]. Moreover, it has been shown that Ang II plays a
cruicalrole in neointimal monocyteinﬁltration through NF-
kappa B activation and monocyte chemoattractant protein-
1(MCP-1) expression an important eﬀe c tt h a ti sb l o c k e d
by angiotensin converting enzyme (ACE) inhibitors [22].
Although Ang II activates NF-kappa B and upregulates
expression of cytokines such as interleukin-6 and tumor
necrosis factor-α, pharmacological blockade of AT1R with
angiotensin receptor blockers would not be so eﬃcient to
inhibit cytokine production entirely [38, 70, 71].
Ang II regulates not only adhesion molecule expres-
sions like vascular cellular adhesion molecule-1 (VCAM-
1), intercellular adhesion molecule-1 (ICAM-1) and P-
selectin but also cytokine, chemokine, and growth factor
secretion within the arterial wall [72]. Alternatively, RAS
can adjust the activation of complement system in both
atherosclerosis and renal injury [73, 74]. This inﬂammatory
cascade accelerate the vascular inﬂammatory response by
elevating inﬂammatory cell recruitment to vessel walls.
After migrating into the vessel wall, monocytes transform
into macrophages and contribute to lipid deposition in
the plaque [75, 76]. Chemokines and MMPs secreted from
monocytes/macrophages cause acceleration of atheroscle-
rotic lesions [77]. Furthermore, angiotensin II favors the
intraplaque recruitment of monocytes and lymphocytes
and directly enhances TNF-α, IL-6 and cyclooxygenase-2
expression in atherosclerotic arteries [1, 78–80]. Moreover
recruited leukocytes themselves have NAD(P)H oxidase
subunits and serve as a source of ROS [81]. In addition,
Ang II triggered activation of transcription factor nuclear4 Cardiology Research and Practice
factor-kappa B through redox-sensitive pathways, induces
cell adhesion molecules as well as the chemokines MCP-
1 and interleukin-8. These molecules promote monocyte
and T-lymphocyte adherence, invasion, and accumulation
in atherosclerotic lesions [22, 24, 37, 82]. Taken together,
these data support a local activated RAS in vessel walls that
promotes inﬁltration of inﬂammatory cells into the vessel
walls, which is an important feature of atherosclerosis.
3.The Functionof LocalBone MarrowRAS
We have recently reviewed the pathobiological aspects of
local hematopoietic BM RAS [83]. The local haematopoi-
etic bone marrow (BM) renin-angiotensin system (RAS)
mediates pathobiological alterations of haematopoiesis in
an autocrine/paracrine/intracrine fashion [84]. Recent data
further indicated the existence of angiotensin-converting
enzyme (ACE) in human primitive lympho-haematopoietic
cells, embryonic, foetal, and adult haematopoietic tissues
[85, 86]. Human umbilical cord blood cells also express
renin, angiotensinogen, and ACE mRNAs [87, 88]. As
ACE and other angiotensin peptides function in human
haematopoietic stem cells (HSCs) throughout haematopoi-
etic ontogeny and adulthood [85, 86], local RAS could also
have a function in HSC plasticity, and the development
of haematological neoplastic disorders [83, 89, 90]. The
presence of ACE on leukaemic blast cells within leukaemic
BM[91,92],onerythroleukaemiccells [93],ACE-expressing
macrophages in lymph nodes of Hodgkin disease [94], renin
activity in leukaemic blasts [95, 96], Ang II as an autocrine
growth factor for AML [97], increased renin gene activ-
ity during NUP98-HOXA9-enhanced blast formation [98],
higherlevelsofBB9/ACE(+)AMLisoforms[85],andaltered
JAK-STAT pathway as a link between RAS and leukaemia
[83, 99] indicated the wide pathobiological aspects of local
BMRAS.LocalhematopoieticBMRASparticularly mediates
pathogenesis of myeloproliferative disorders (MPDs) [83].
JAK-STAT pathway represents the point of crosstalk between
the upstream local BM RAS and neoplastic hematopoiesis
[83, 99]. Abnormally enhanced expressions of the main
RAS components in MPD are downregulated by the tar-
geted therapy, imatinib mesylate [100]. JAK1 and JAK2
inhibitor, INCB018424, decreased clonal neoplastic cells and
downregulated inﬂammatory responses in MPD [101].Since
neoplasia and inﬂammation are the main pivotal actions of
hematopoietic BM RAS, which is the upstream controlling
pathway of JAK-STAT signaling [83, 102]; direct eﬀects of
INCB018424onRASshall be further searched to understand
its clinically translated pleiotropic molecular engagements.
The comparable biological actions of local RASs throughout
thehuman body (includingmyocardium, pancreas, pituitary
gland, ovary, and kidney) represent the true basis for the
search of their prominence in tissue functions [83].
Interestingly a previous study provided by Savary et al.
[103] demonstrated the presence of a locally active RAS
in the yolk sac and possible RAS-dependent participation
of ACE in the modulation of early yolk sac erythropoiesis.
Moreover the discovery that ACE/CD143 marks primitive
embryonic hemangioblasts raised the probability that the
versatile RAS plays a crucial role in regulating the earliest
stages of human hematoendothelial diﬀerentiation, as it
does in avian embryos. Zambidis et al. [104] successfully
demonstrated a dramatic upregulation of AT2R during
expansion of human embryoid body (hEB)-derived ACE+
hemangioblasts,whichproposesanexclusiverolefortheRAS
in guiding the early developmental phases of human angio-
hematopoiesis[105–107].FurthermoretheyfoundthathEB-
derived blast-colony-forming cell could be targeted to dif-
ferentiate into either hematopoietic or endothelial progeny
by manipulating signaling pathways normally mediated by
the RAS. And also manipulation of angiotensin II signaling
with either AT1R or AT2R speciﬁc inhibitors toward either
endothelium, or multipotent hematopoietic progenitors,
resulted in obvious deviations of hEB diﬀerentiation [105].
4.Local HaematopoieticBone Marrow
RASinthePathogenesisofAtherosclerosis
There is a close interrelationship between hematopoietic
bone marrow RAS and the cardiac RAS [105, 106]. Myocar-
dial tissue repair via hematopoietic stem cell plasticity may
represent a point of crosstalk between local cardiac RAS and
hematopoieticRAS(Figure1)[89,108].Inﬂammatory medi-
ators particularly macrophages/monocytes, neutrophils and
T-lymphocytes play a central role in all phases of atheroscle-
rosis. Atherosclerotic lesions are initiated by endothelial
cell damage, followed by monocyte/macrophage adhesion
and invasion as well as smooth muscle cell migration and
proliferation [109, 110]. In this perspective, restenosis after
angioplasty shares a common pathophysiological process
with atherosclerosis, where endothelial injury followed by
impaired endothelialization [111, 112]. Previously it has
been believed that only migration and proliferation of
adjacent endothelial cells in the vessel wall causes re-
endothelialization, but afterwards it has been proved that
endothelialprogenitor cells derived from bone marrow (BM)
also participate in this course [113–115]. A local RAS in BM
hasapossibleroleinendothelialprogenitorcellbiologycaus-
ing neovascularization. Recently it has been demonstrated
that RAS activation stimulates endothelial progenitor cell
proliferation and neovascularization [26, 116].
Strawn et al. was the ﬁrst to propose a lipid-angiotensin
system connection within the BM that accounts for the
predisposition of immune cells to home to coronary
arteries and initiate atherosclerosis [117, 118]. Their data
supported a positive regulatory role of plasma LDL on
AT1R-mediated haematopoetic stem cell diﬀerentiation and
the production of proatherogenic monocytes which may
explain in part hypercholesterolemia-induced inﬂammation
as well as the anti-inﬂammatory and antiatherosclerotic
eﬀects of AT1R blockers. This innovative theory combines
theformerlipidhypothesesandallowsforan immunological
activation concept that begins as early as changes in the
BM that result in the generation of activated circulating
monocytic phenotypes that participate in atherogenesis. The
“bone marrow response-to-lipid” hypothesis incorporatesCardiology Research and Practice 5
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Figure 1: Possiblefunctions of hematopoietic stem cells in the vasculature and cardiac microenvironment, suggesting the interrelationships
of local bone marrow renin-angiotensin system (RAS), circulating RAS, and local myocardial RAS.
the idea that proatherogenic properties of hematopoietic and
nonhematopoietic progenitors are determined by the local
actionsofmodiﬁedLDLontheexpression oflocalRASgenes
[117].
Fukuda and Sata successfully demonstrated that BM-
derived cells signiﬁcantly contribute to the development
of atherosclerotic lesions [21, 26, 119]. Although Ang
II is supposed to promote contribution of BM-derived
cells to atherosclerosis by enhancing their mobilization,
recruitment, diﬀerentiation, and proliferation, Fukuda and
Sata performed an experiment for to evaluate the potential
participation of AT1aR in BM in the pathogenesis of
atherosclerosis. They generated several combinations of BM
chimeric mice in a murine model of hyperlipidemia and6 Cardiology Research and Practice
atherosclerosis byanalyzing severalBMchimeric mice whose
BM cells were positive or negative for AT1aR. They also
mentioned that Ang II infusion increased the number of
smooth muscle progenitor cells, which are peripheral blood
cells that turn to α-smooth muscle actin-positive cells after
culture in the presence of PDGF-BB. These smooth muscle-
like cells expressed abundant matrix metalloproteinase-9
(MMP-9), which substantially contribute to destabilization
of atherosclerotic plaques [21]. Their results suggested that
blockade of AT1R not only in vascular cells but also in
BM could be an important strategy to prevent atheroscle-
rosis. In a previous study by Cassis et al. [120]i th a s
been shown that, bone marrow recipient AT1a receptors
are required to initiate Ang II-induced atherosclerosis in
hypercholesterolemicmiceinwhich bonemarrow transplan-
tation studies were performed. They have concluded that
AT1a receptors expressed on inﬁltrating cells exert modest
regulation of Ang II-induced atherosclerosis. Moreover the
existenceofthisreceptorinresidenttissueisnecessary forthe
initiation of Ang II-induced atherosclerosis and abdominal
aortic aneurysms. An other study by Tsubakimoto et al.
[121], the Ang II regulated diﬀerentiation/proliferation
of monocyte-lineage cells to exert proatherogenic actions
was clearly deﬁned. In this study the authors generated
BM chimeric apoE negative mice repopulated with AT1-
deﬁcient (Agtr1−/−) or wild-type (Agtr1+/+)) BM cells. The
atherosclerotic development was signiﬁcantly reduced in
apoE−/−/BM-Agtr1−/− mice compared with apoE−/−/BM-
Agtr1+/+ mice, accompanied by decreased numbers of BM
granulocyte/macrophage progenitors and peripheral blood
monocytes. And ﬁnally they have been proposed that Ang
II controls the expression of c-Fms in HSCs and monocyte-
lineage cells through BM stromal cell derived TNF-alpha
to promote M-CSF–induced diﬀerentiation/proliferation of
monocyte-lineagecellsandcontributestothe proatherogenic
action [121].
In contrary to the studies demonstrating that [21, 122]
blockade of AT1 receptor in BM cells might have inhibitory
eﬀects on atherosclerosis, little or no changes of atheroscle-
rosis in LDL receptor knockout mice by transplantation
with BM from AT1a receptor knockout mice are also
reported [120, 123]. These reports suggest the ameliorative
function of AT1 receptor blockade in vascular cells for
the AT1 receptor blocker- (ARB-) mediated atherosclerosis
inhibition. In conjunction with the latter reports, the study
by Kato et al. [124] also demonstrates that the beneﬁcial
eﬀects of ARB in end-organ injuries are due to the blockade
of AT1 receptor expressed in the end organs, but not
in bone-marrow-derived cells. They proposed that distinct
results observed in the kidney injury and atherosclerosis
is possibly from the diﬀerences in the pathogenesis of
mouse models. Moreover they have speculated that depend-
ing upon the tissues and model systems examined, AT1
receptor function in BMDCs may have diﬀerential action
points.
Taken as a whole, the hematopoietic BM RAS, as well as
local vasculature RAS, plays a crucial role in the initiation
and progression of atherosclerosis, thereby contributing to
development of cardiovascular diseases.
5.FutureTherapeuticPerspectives
Endothelial dysfunction, cellular proliferation, and pro-
grammed inﬂammation triggered by RAS provide a clue
to a novel understanding of the pathological hallmark
of atherosclerosis, and may be important in developing
new antiatherosclerotic strategies. AT1aR expressed on BM-
derived cells plays a crucial role in the pathogenesis of
atherosclerosisbyacceleratingBM-derivedinﬂammatory cell
inﬁltration in the vessel wall. Forthat reason, AT1R blockade
not only in vascular cells but also in BM could help to
prevent progression and destabilization of atherosclerotic
plaques [21, 26, 117, 119, 125]. Pharmacological therapeutic
strategies must focus on the distribution and the density
of angiotensin receptors, gene expression, and proteomics
along hematopoietic BM structures. Future therapeutic
interventions would interfere with the pathobiological acti-
vation of the local hematopoietic BM in a variety of diseases,
particularly atherosclerosis, to elucidate the importance of
the system from an actual clinical point of view.
In summary, a large number of studies have shown that
RAS has a central role in the initiation and progression of
atherosclerosis, as outlined in this paper. Ang II may com-
promise the structural integrality of the endothelial barrier
by induction of endothelial cell apoptosis. Inﬂammatory
reaction in the vascular intimal layer involving macrophages
and T lymphocytes by RAS-induced oxidative stress and
hyperthrombotic state results in oxidative lipoprotein mod-
iﬁcation, smooth muscle cell migration from the media
into the intima, proliferation, and transformation from a
contractile to a synthetic phenotype. While the earlier stages
may remain subclinical, this stage of the atherosclerotic
process leads to a signiﬁcant reduction in the vessel lumen.
AT1aR expressed not only on vascular cells but also on
BM-derived cells plays a role in the atherosclerotic plaque
pathogenesis, at least partially by accelerating inﬁltration of
BM-derived inﬂammatory cells in the vessel wall. Under-
standing the diversity of intracellular Ang II synthesis
pathways may help in developing therapeutic interventions,
and blockade of AT1R not only in vascular cells but also in
BM could be an important strategy to prevent progression
and destabilization of atherosclerotic plaques.
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